ClinicalTrials.gg
Active, not recruitingNCT05912790Updated Aug 31, 2023

eyeTube in Combination With the eyeWatch Implant

An interventional study of eyeTube in Aqueous Humor Drainage, sponsored by Rheon Medical SA. Active, not recruiting at 1 site in Senegal. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Rheon Medical SA · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

In this study, the investigators want to investigate the success of aqueous humor shunting in the retrobulbar space, using the eyeTube in combination with the eyeWatch implant. The investigators postulate that posterior aqueous humor shunting would be more effective, as this space offers a larger drainage area and a less aggressive local inflammatory environment than the subconjunctival space close to the limbus, resulting in lower and better-sustained IOP than in the more limited, fibroblast-promoting subconjunctival environment surrounding standard implants.

02

Conditions studied

  • Aqueous Humor Drainage
03

In context

Lead sponsor

Rheon Medical SA is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Men and women aged 18 to 85.
  • Diagnosis of primary open-angle glaucoma meeting both of the following criteria:
  • IOP uncontrolled by at least one (1) or more classes of topical IOP-lowering medical therapy, and
  • Failure of at least one (1) conventional intraocular glaucoma surgery (e.g., glaucoma filter surgery or tube shunting) or cilioablative procedures (e.g., cryotherapy, cyclodiode therapy).
  • Trabecular meshwork visible on gonioscopy, with a Shaffer angle ≥ 3 in the target quadrant.
  • Patients must be able to understand the study requirements and provide written .
  • Patients must be willing to follow study instructions, agree to comply with all study procedures and be able to attend all scheduled follow-up examinations for at least 12 months after surgery.

Exclusion criteria

Exclusion Criteria:

    • Previous filtering surgery, secondary glaucoma, severe systemic disease, pregnancy, breast-feeding, inability to understand or give .
  • Choroidal detachment, choroidal effusion or any active choroidopathy.
  • Diagnosis of acute angle-closure glaucoma or malignant glaucoma.
  • History of glaucoma drainage/valve implant in target quadrant
  • Presence of conjunctival scarring, previous conjunctival surgery or other conjunctival pathology (e.g. pterygium) in the target quadrant.
  • Use of systemic (oral or intravenous) glaucoma medications
  • History of corneal surgery (including LASIK and PRK), corneal opacities, corneal diseases or any corneal pathology likely to interfere with IOP measurement.
  • Eyes with ocular malformations such as microphthalmia
  • Eyes with concomitant inflammatory/infectious ocular disorders
  • Aphakia
  • Presence of an anterior chamber intraocular lens or implantable contact lens
  • Previous complicated cataract surgery or presence of vitreous in the anterior chamber
  • Cataract surgery performed less than 6 months before the start of the study
  • Presence of intraocular silicone oil
  • Previous diagnosis of chronic uveitis in either eye
  • Active diabetic retinopathy, choroidal neovascularization, secondary retinal vein occlusion, central retinal vein occlusion, proliferative retinopathy or other ophthalmic disease or disorder likely to distort study results.
  • Impaired episcleral venous drainage (e.g., Sturge-Weber or nanophthalmos or other evidence of elevated venous pressure)
  • Uncontrolled systemic disease (e.g. diabetes, hypertension)
  • History of dermatological keloid formation
  • Use of ocular or systemic in the last 30 days (chronic continuous use of systemic steroids is permitted) prior to the screening visit, or known response to corticosteroids.
  • Pregnant or breast-feeding women, or women of childbearing age who do not wish to use medically acceptable between the screening visit and the 12-month follow-up visit.
  • Known or suspected allergy or to any component of the device (e.g. silicone).
  • Current participation or participation within the last 30 days (from the screening visit) in another clinical trial of an drug or interventional device.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Treated with the eyeTube

    Device: eyeTube

Interventions

  • DeviceeyeTube

    Implantation of a drainage device in the eye, in combination with the eyeWatch implant

06

What researchers measure

Primary outcomes

  1. Intraocular pressure (IOP) reduction

    The proportion of subjects achieving a mean reduction in IOP of ≥ 20% compared with pre-operative pressure at 12 months with the same or fewer hypotensive drugs.

    Time frame: 12 months

  2. Adverse events

    The incidence and severity of adverse events in the study eye (overall and related to the eyeWatch system) throughout the follow-up period.

    Time frame: 12 months

07

Study locations

1 site
  • Senghor Centre
    Mbour, Senegal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05912790
Lead sponsor
Rheon Medical SA
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Jun 6, 2023
Primary completion
Jun 20, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Aug 31, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion